GNMXCorgi Genomics & Precision Medicine ETF
Seeks capital appreciation.
By Corgi · Launched 2026
Annual Cost
0.35%
#1,731 of 6,166 · low cost
Fund Size
$2M
#5,707 of 6,166 · small
Return (1Y)
N/A
Track Record
4 months
#5,432 of 6,166 · young
Performance
Total-return NAV · USDGrowth of $10,000
$15,027+50.3%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundHoldings
By weightConcentration
Top 10 holdings = 44.3% of fundmoderately concentrated
Thermo Fisher Scientific IncTMO
8.4%
Moderna IncMRNA
6.6%
Vertex Pharmaceuticals IncVRTX
6.5%
Illumina IncILMN
4.0%
Revolution Medicines Inc Ordinary SharesRVMD
3.6%
Guardant Health IncGH
3.5%
Incyte CorpINCY
3.0%
10x Genomics Inc Ordinary Shares - Class ATXG
2.9%
Genmab AS ADRGMAB
2.9%
Alnylam Pharmaceuticals IncALNY
2.7%
Asset allocation
Stocks
97.3%
Cash
2.7%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
N/A
Max drawdown
-8.5%Mild
Worst peak-to-trough loss
Sharpe (3Y)
Unavailable
Needs 3+ years of history
Sortino (3Y)
Not yet
Needs 3+ years of history
Listing
- Exchange
- Cboe BZX
Full fund details
- Objective
- Seeks capital appreciation.
- Strategy
- Actively manages a portfolio primarily invested in common stocks of companies materially involved in genomics and precision medicine. Invests in U.S. and foreign companies across any market capitalization, employing a bottom-up security selection process combining fundamental analysis with thematic and quantitative screening.
- Inception date
- May 5, 2026
- Fund family
- Corgi
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save GNMX to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-30